We assessed monthly doses of tafenoquine for preventing Plasmodium vivax and multidrug-resistant P. falciparum malaria. In a randomized, double-blind, placebo-controlled study, 205 Thai soldiers received either a loading dose of tafenoquine 400 mg (base) daily for 3 days, followed by single monthly 400-mg doses ( ), or placebo ( ), for up to 5 consecutive months. In volunteers completing follow-up (96 n p 104 n p 101 tafenoquine and 91 placebo recipients), there were 22 P. vivax, 8 P. falciparum, and 1 mixed infection. All infections except 1 P. vivax occurred in placebo recipients, giving tafenoquine a protective efficacy of 97% for all malaria (95% confidence interval [CI], 82%-99%), 96% for P. vivax malaria (95% CI, 76%-99%), and 100% for P. falciparum malaria (95% CI, 60%-100%). Monthly tafenoquine was safe, well tolerated, and highly effective in preventing P. vivax and multidrug-resistant P. falciparum malaria in Thai soldiers during 6 months of prophylaxis.
as a safer, more effective, and long-acting prophylactic against all species of malaria, has undergone extensive preclinical toxicological and microbiological evaluation and has progressed through single-and multiple-dose escalation phase 1 studies and limited phase 2 evaluations [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In particular, a double-blind, placebocontrolled study showed that Kenyan adults who received only a 3-day tafenoquine loading dose (400-mg base/day) were protected against P. falciparum malaria for up to 7 weeks (82% protective efficacy) [6] . Similar protection was seen in a dose-ranging study in children and young adults in Gabon, where a 3-day loading of only 200-mg base/day provided 100% protection (95% confidence interval [CI] , 71%-100%) for 10 weeks in a region where P. falciparum is highly endemic [11] .
The prolonged period of protection after 3-day loading doses in Kenya and Gabon was likely associated with tafenoquine's long elimination half-life in humans of ∼14 days [8, 9, 19] . In the present study, we aimed to extend the boundaries of tafenoquine's capability by administering it as a 3-day loading dose, followed by single monthly doses (every 4 weeks), to malaria-naive or semi-immune Thai soldiers deployed for up to 6 months in northeastern Thailand, an area where both P. vivax and multidrugresistant P. falciparum are endemic [20, 21] .
SUBJECTS AND METHODS
Trial design and participants. The study was randomized, double-blind, and placebo-controlled and was conducted from April to November 1998 in Nam Yun District, Ubol Ratchatani Province, Thailand, an area where P. vivax and multidrug-resistant P. falciparum malaria are endemic [20, 21] . The peak malaria transmission in this region generally occurs between April and October. The study was designed to test a hypothesis that a 3-day loading dose of tafenoquine, followed by single monthly doses, would be effective in preventing malaria for up to 6 months in deployed Thai soldiers. The primary efficacy outcome was the first appearance of malaria on a blood smear during the double-blind period of the study. Secondary outcomes were safety and tolerability.
Royal Thai Army and border patrol soldiers were eligible for enrollment if they were being deployed to the endemic site, provided written, informed consent, were 18-55 years old, were in good general health, had 2 normal glucose-6 phosphate dehydrogenase (G-6PD) screens (methemoglobin [MHb] reduction test and Boehringer Mannheim fluorescent assay; Boehringer Mannheim Diagnostics), and had not received antimalarial treatment within the preceding 2 weeks (5 weeks for mefloquine).
The study was approved by the US Army Human Use Research Review Board and the institutional review boards of the Royal Thai Army, the Thai Ministry of Public Health, and the Thai Food and Drug Administration. The protocol was part of an investigational new drug application filed with the US Food and Drug Administration and was conducted according to Helsinki Declaration (1989) and Good Clinical Practices guidelines. Study monitoring was conducted by the Quality Assurance Office, Armed Forces Research Institute of the Medical Sciences, the US Army Medical and Materiel Development Activity, and SmithKline Beecham Pharmaceutical Company.
Interventions, procedures, and test articles. All volunteers were examined for malaria parasites and received a 7-day course of artesunate (600 mg total over 3 consecutive days) and doxycycline (100 mg daily for 7 consecutive days), administered concurrently, to eliminate any subpatent blood stages of malaria. The short half-lives of these drugs precluded any prophylactic carryover effect into the start of the double-blind medication period [22, 23] . Most army soldiers received presumptive therapy at their malaria-free barracks, ∼100 km from the malarious study site, whereas border patrol soldiers received presumptive therapy at the study site. In any soldier with patent parasitemia, clearance of parasites was confirmed at the end of presumptive therapy by examination of at least 2 thick blood smears obtained 8 h apart.
After completing presumptive therapy, volunteers were randomized to receive either tafenoquine (400-mg base) daily for 3 days and then 400 mg monthly for up to 5 more months or placebo on the same dosing schedule. For the first dose of prophylaxis, all subjects were at the study site where malaria is endemic. Monthly doses were administered under direct observation within a window of 25-31 days after the previous dose and within 2 h of a meal or light snack, for better gastrointestinal (GI) tolerance and bioavailability [8, 9] . Volunteers who developed parasitemia while they were receiving medication and who were classified as having had treatment failure received the presumptive therapy regimen and were given the option of no further prophylaxis, doxycycline at 100 mg daily, or open-label tafenoquine administered at a dose of 400 mg for 3 days for loading and then 400 mg weekly.
Thick blood smears were collected and examined at least weekly during the period of medication and for up to 3 months after completion of the study. Two hundred oil-immersion fields (magnification, ϫ1000) were read on Giemsa-stained thick blood smears by 2 independent readers (1 US Army and 1 Royal Thai Army). The 2 readers remained blinded to the other's results by reading slides at different times of the day and in different areas of the laboratory. Discrepancies between the results of the 2 microscopists were adjudicated by the senior on-site technologist, with 1 reading ultimately recorded. Malaria infection was defined as the presence of Plasmodium asexual-stage parasites on a thick blood smear, with species (P. vivax or P. falciparum) determined by examination of thin smears.
Complete blood counts (CBCs) and hepatic and renal function tests were conducted monthly and then for up to 2 months after the last medication. MHb levels, measured weekly by use of an OSM 3 hemoximeter (radiometer) [5] , were monitored in a manner that did not affect blinding. Adverse events (AEs) were recorded daily during the 3-day loading dose and then at approximately 24 h after each dose, according to a predefined coded checklist of the most commonly expected AEs. Serious AEs were defined as those that required hospital admission.
Artesunate tablets were obtained from Atlantic Pharmaceutical, and doxycycline (Rugby Pharmaceuticals) was obtained from the US Army Central Formulary (Fort Detrick, Frederick, Maryland). Tafenoquine (WR238605/SB 252263 {8-[(4-amino-1-methylbutyl)amino]-2, 6-dimethoxy-4-methyl-5(3-trifluoromethylphenoxy} quinoline, succinate) was manufactured by SmithKline Beecham and was supplied as opaque green capsules that contained 250 mg of succinate salt (equivalent to 200-mg base). Identical-appearing placebo capsules contained inert powder of the same color and consistency as tafenoquine capsules. For open-label dosing, tafenoquine capsules were pack- aged in plastic bottles. All study drugs were stored in a secure refrigerator at 4ЊC.
Sample size, randomization plan, allocation, and concealment. The sample size was determined to have 80% power to detect at least an 85% reduction (tafenoquine vs. placebo) in the 6-month cumulative incidence (attack rate) of slideproven malaria. On the basis of historical attack rates, the incidence of malaria over a 6-month period was expected to be at least 15% in the placebo group and 2.25% [15% ϫ (1Ϫ0.85)] in the tafenoquine group. On the basis of 80% power to detect this difference (Fisher's exact test; , 2-sided), 90 vola p 0.05 unteers were required in each treatment group [24] .
Volunteers were randomized to 1 of 2 groups (tafenoquine or placebo) by use of computer-generated blocked randomization with a block size of 12, which approximated platoon sizes (units with similar exposure). The randomization list was prepared by SmithKline Beecham (which was not directly involved with the study), which also maintained the code linking each subject to a treatment. Another copy of the code was kept off-site by the medical monitor. Enrollment and assignment to groups were conducted by 2 investigators (D.W. and C.E.) within 48 h of the first loading dose. All investigators, technicians, and participants remained blinded throughout the study.
Data management and statistical analysis. Study data were entered twice into a computerized spreadsheet (Excel) and cross-checked for agreement. All data discrepancies were resolved and final diagnoses made before the treatment code was unblinded. Minitab (version 13; Minitab) and StatXact (version 4.01; Cytel Software) were used for statistical analysis.
All randomized volunteers who had received at least 1 dose of medication were included in the analysis of safety and tolerability, and all randomized volunteers who had received at least 1 dose of medication and had attended at least 1 ontherapy efficacy assessment with a blood smear were included for the analysis of efficacy (intent to treat). The primary efficacy end point was the incidence of subjects with a first occurrence of microscopically confirmed P. vivax or P. falciparum malaria. No volunteers were withdrawn from the study if they were still available for follow-up. The follow-up time was measured from the first dose of tafenoquine (day 0) until the date of drug failure, withdrawal from the study (non-malaria related), loss to follow-up, or study completion (6 months for most volunteers). The study closing date was the same for all volunteers.
Cumulative attack rates were computed as the proportion of volunteers who completed the study according to our protocol who became infected (first occurrence of parasitemia). Incidence (density) rates were calculated as the number of cases (first occurrence) of malaria divided by the total person-time of follow-up. The primary estimate of protective efficacy (PE; tafenoquine vs. placebo) was defined as the percentage reduction in cumulative attack rates. Koopman's method was used to calculate corresponding CIs for PE on the basis of the ratio of 2 proportions [25] . PE was also calculated as the percentage reduction in incidence (density) rates. Corresponding CIs based on the ratio of 2 Poisson variables were calculated by use of the exact conditional distribution [26] . All reported CIs are 95%, and all P values are 2-sided.
Proportions were compared by use of Fisher's exact test [27] . The primary follow-up time for incidence (density) analysis was the total time in study, including any leave time away from the main exposure area (time in the endemic area plus leave time). Analysis was also done with time in the endemic area, to account for possible effects of differential exposure to malaria.
Cumulative risk curves (Kaplan-Meier) were compared by use of the log-rank test. Follow-up was considered to be censored for volunteers with unknown outcomes (withdrawals or lost to follow-up), and follow-up time beyond the closing date of the study, when troops were recalled to a nonmalarious area, was excluded from efficacy analysis.
Monthly hematologic and biochemical laboratory values were recorded and the changes from baseline assessed. Group treat- ment means (95% CIs) were computed and compared by use of Student's t test (unpaired and paired if appropriate). AEs were summarized by the 2 treatment arms, but the study was not designed to reliably estimate AE rates of low incidence or to have sufficient power to detect differences between the 2 groups.
RESULTS
Subject demographics, enrollment, and disposition. Volunteer enrollment and time lines are depicted in figures 1 and 2. Of 263 volunteers registered, 205 were randomized and received at least 1 dose of study medication (safety population); these subjects also provided at least 1 blood smear during the doubleblind phase to assess efficacy (intent-to-treat population). Eighteen of 205 volunteers who arrived at the study site ∼3 months later than the rest of the soldiers, who had presumptively been treated before deployment and then randomized to doubleblind prophylaxis, were designated cohort 2 but were analyzed jointly with the main cohort (cohort 1) (figure 2). Seventeen subjects (8.3%) were lost to follow-up (figure 1). For placebo recipients, 5 were reassigned to distant posts and 4 left the service; for tafenoquine, 6 were reassigned and 2 left the service.
Participants in both treatment arms had a median age of 23 years, and approximately one-half described previous malaria infections. Before receiving the artesunate-doxycycline presumptive treatment, patent parasitemia was observed in 9 tafenoquine (5 P. vivax and 4 P. falciparum) and 9 placebo (6 P. vivax and 3 P. falciparum) recipients. Volunteers remained in the malarious area throughout the period of double-blind dosing and did not return to their malaria-free barracks sooner than 1 month after the last dose.
Protective efficacy. For up to 6 months of prophylaxis, tafenoquine conferred a PE of 97% (95% CI, 82%-99%) against all malaria, 96% (95% CI, 76%-99%) against P. vivax malaria, and 100% (95% CI, 60%-100%) against P. falciparum malaria (table 1 and figure 3 ). PE based on the percentage reduction in incidence (density) rates gave similar results using either time in study or time in the endemic area (table 1). The single tafenoquine failure, a P. vivax infection, was detected 35 days after the second monthly dose, on the day that the volunteer returned from leave and was about to receive the third monthly dose. This volunteer remained well after his second tafenoquine dose, with no vomiting or diarrhea. All 31 parasitemic volunteers received curative treatment and elected to receive a weekly open-label 400-mg tafenoquine regimen. None developed malaria during weekly prophylaxis.
Five tafenoquine and 4 placebo recipients developed parasitemia 11 month after the last monthly medication. P. vivax was observed 44-76 days after the last dose of double-blind medication in 1 placebo and 3 tafenoquine recipients, at least 5 weeks after their departure from the malarious area. Parasitemia had not been detected in any of these volunteers during the prestudy screening period. P. falciparum was observed 78-93 days after the last dose of double-blind medication in 3 placebo and 2 tafenoquine recipients while they were still patrolling in malarious areas.
Safety. Nonserious AEs occurring within 24 h of receiving double-blind study medication were reported by 70% (73/104) of tafenoquine recipients and 55% (56/101) of placebo recipients (  ; table 2 ). Of the coded AEs, headaches, GI P p .041 disturbances, and vertigo were most common for all volunteers, with GI complaints (loose stools, nausea, or vomiting) being significantly more common among tafenoquine recipients than among placebo recipients ( , Fisher's exact P р .001 test, 2-sided). For tafenoquine recipients, GI complaints were slightly more frequent after completing the 3-day loading dose than during monthly dosing.
For open-label weekly tafenoquine dosing, 74% of volunteers reported у1 AE. In comparison with monthly tafenoquine, nausea or vomiting and vertigo were more frequent during open-label doses, whereas loose stools were more frequent with monthly than weekly dosing (31% and 19%, respectively). For both blinded and open-label volunteers, the rate of noncoded AEs was unremarkable. Table 3 shows nonfatal serious AEs that occurred in 9 volunteers during double-blind or open-label phases. For the placebo recipient with syncope, a diagnosis was not made, and he returned to duty with no further incidents. There were no withdrawals or missed prophylactic doses due to any AE. Most tafenoquine recipients had transient, asymptomatic elevations of MHb (normal MHb, р3%) (figure 4). During monthly prophylaxis, 22% (23/104) of tafenoquine recipients had an MHb level у3.0%, with a maximum individual value of 6.9%. During weekly open-label tafenoquine, the highest recorded MHb value was 9.8%. The maximum values in both monthly and weekly tafenoquine prophylaxis occurred shortly after the 3-day loading doses. For CBCs, there were no significant differences between the mean monthly values of the tafenoquine and placebo recipients for any parameter throughout the study or any significant changes from baseline values in either group.
For hepatic enzymes, 12 subjects (7 tafenoquine and 5 placebo recipients) had at least 1 alanine aminotransferase (ALT) value above the extended clinical range (70 U/L; 2 times the upper limit of normal [ULN]). Three subjects (2 tafenoquine and 1 placebo recipient) with elevated ALT levels also had at least 1 aspartate aminotransferase (AST) value above the extended clinical range (100 U/L; 2 times ULN). All elevated transaminase values were transient and were not associated with symptoms. The highest transaminase values were observed in a tafenoquine recipient (ALT, 461 U/L; AST, 260 U/L) who was diagnosed with chronic hepatitis B infection. For renal function, creatinine levels were transiently elevated in some tafenoquine (11 [11%] ) and placebo (3 [3%] ) recipients (range, 2.3-2.7 mg/dL [1.5-1.8 times ULN]). These elevations, which occurred between the 3 loading doses and the first monthly double-blind dose, returned to normal by the second month dose.
DISCUSSION
The prophylactic efficacy of tafenoquine has so far only been assessed in Africa, where P. falciparum is the dominant plasmodial species. Our study in Thailand was designed to determine whether P. vivax, as well as multidrug-resistant P. falciparum, would be equally susceptible to tafenoquine. In the 3 previous African studies, weekly doses of tafenoquine were highly effective in suppressing falciparum malaria [6, 10, 11] . Because of the prolonged period of protection observed in the African studies after only a 3-day loading dose of tafenoquine, we posited that intermittent administration of tafenoquine at 400 mg once a month might be effective in suppressing both P. falciparum and P. vivax. This is in contrast to the African studies, where the prophylactic efficacy of weekly regimens of 25-200 mg was assessed [6, 10, 11] .
Our results clearly indicate that monthly tafenoquine administration, preceded by a loading dose, is highly effective in preventing both major forms of malaria during a prolonged period of prophylaxis. The single prophylactic failure in the tafenoquine recipients, a case of P. vivax infection, was detected 35 days after the second monthly tafenoquine dose. Of note, this volunteer missed the third scheduled monthly dose (having been on leave), and parasites were detected 1 week later, just as he was to receive his third dose. His plasma tafenoquine concentration (40 ng/mL at the time of diagnosis) was ∼3-fold lower than tafenoquine concentrations found for other soldiers who did not develop parasitemia 28 days after the second monthly dose [28] . The low tafenoquine concentration was probably responsible for not preventing patent parasitemia in this volunteer.
The data from volunteers who developed malaria after the end of prophylaxis may provide some added insight into the potential value of tafenoquine for malaria prophylaxis. Falciparum malaria was to be expected in those soldiers who continued to be exposed to malaria transmission. However, 3 overt cases of P. vivax malaria observed in tafenoquine recipients who had left the malarious area some time previously suggest that these infections had probably been acquired while they were still receiving tafenoquine prophylaxis. These observations indicate that, although tafenoquine inhibited the blood stages very effectively, monthly prophylaxis was not entirely effective against the liver stages of P. vivax and, therefore, might not always prevent P. vivax malaria after the end of prophylaxis. Because liver stages of P. vivax in Thailand can be refractory to 8-aminoquinolines [29] , it is possible that these 3 soldiers were infected with such parasites.
Like other 8-aminoquinolines, tafenoquine is contraindicated in pregnancy and in G-6PD-deficient persons [6, [8] [9] [10] . We conducted 2 screens, which we felt was necessary given the variable amounts of hemolysis that can occur if a G-6PD-deficient person receives tafenoquine [6, 8, 9] . As in previous studies, we observed transient MHb elevations in tafenoquine recipients, with a peak value of 6.9% in monthly recipients and 9.8% in the weekly recipients occurring shortly after loading doses [5] . Although a normal MHb level is р3%, symptoms usually begin at 15%-20% [30] . All soldiers, including those who were receiving weekly tafenoquine, remained asymptomatic, even during exertion. Similar to other studies, tafenoquine was associated with significantly more GI complaints than placebo, including loose stools and nausea [5, 9, 10] . Modest transient elevations in transaminases, especially ALT, were observed in slightly more tafenoquine recipients, similar to other studies [5, 10] . Transient elevations in creatinine levels, observed early during the study in 11 tafenoquine and 3 placebo recipients, has not been previously reported, and the etiology was unclear [5] [6] [7] [9] [10] [11] [12] . Other AE rates were similar to those in other placebo-controlled studies [6, 10, 11] .
Further studies are warranted to better define the safety, tolerability, and optimum dosage of tafenoquine. However, as shown here, the prolonged suppression of both multidrug-resistant falciparum and vivax malaria, even when dosed monthly, stands out as the dominant feature of this drug. Monthly prophylaxis would be more convenient than weekly or daily dosing and would likely improve compliance. For short-term travelers or soldiers on temporary deployment to malarious areas, a loading dose followed by a few monthly doses of tafenoquine might provide sufficient protection against malaria for the duration of their stay. However, all potential users of tafenoquine would require screening for G-6PD deficiency, to prevent druginduced hemolysis, and women of childbearing potential should undergo pregnancy testing and use birth control as appropriate. Despite these handicaps, tafenoquine's role in the chemoprophylaxis of malaria deserves further evaluation.
